107. Hamm JT, Allegra JC. New hormonal approaches to the treatment of breast cancer. *Crit Rev Oncol Hematol* 1991; 11: 29-41
108. Lippmann ME, Swain SM. Endocrine-responsive cancers of humans. In: Wilson JD, Foster DW, editors. *Williams textbook of endocrinology*. 8th ed. Philadelphia: W.B. Saunders Company, 1992: 1577-97
109. Dowsett M. Novel approaches to the endocrine therapy of breast cancer. *Eur J Cancer* 1990; 26: 989-92
110. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. *J Clin Oncol* 1996; 14: 2000-11
111. Muss HB, Case LD, Capizzi R, et al. High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. *J Clin Oncol* 1990; 8: 1797-805
112. Robertson JFR, Williams MR, Todd J, et al. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. *Eur J Cancer Clin Oncol* 1989; 23: 469-75
113. Dixon AR, Jackson L, Chan S, et al. A randomized trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant breast cancer. *Br J Cancer* 1992; 66: 402-4
114. Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. *J Natl Cancer Inst* 1995; 87: 645-51
115. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. *Lancet* 1989; i: 117-20
116. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. *J Natl Cancer Inst* 1994; 86: 527-37
117. Jordan VC. Alternate antiestrogens and approaches to the prevention of breast cancer. *J Cell Biochem* 1995; 22: 51-7

Correspondence: Lynda R. Wiseman, Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.
E-mail: demail@adis.co.nz

Errata

Vol. 53, No. 4, page 595: In table I, the following corrections should be made: the number of nodes in TNM stage II at Duke's stage B1 should be 0; the Duke's stage in TNM stage II tumour type T4 should be B3; the tumour type of TNM stage III at Duke's stage C1 should be T1-T2; and metastases at TNM stage IV should be +. In the table legend the following abbreviation should be added: + = *presence of distant metastases*.

page 600: In table V, the survival in weeks of the Erlichman et al.[67] study should read 54 vs 41.

page 602: In section 2.1.2, the first sentence should read: 'Phase II studies . . . USA; irinotecan was administered at a dosage of 125 to 350 mg/m² every 1 to 3 weeks.'

page 604: In table VIII, in regimen 3 the dosages (mg/m²) of MTX and FU should read 200^b and 600^b, respectively.

[Labianca R, Pessi MA, Zamparelli G. *Treatment of colorectal cancer: current guidelines and future prospects for drug therapy. Drugs* 1997 Jan; 53 (4): 593-607]